Amgen Inc. ($AMGN) Stock Forecast: Up 7.7% Today

What is Amgen Inc.?

Amgen Inc. (AMGN) is a multinational biopharmaceutical company headquartered in California, known for developing innovative medicines to treat serious illnesses. Market: The overall market sentiment for Amgen Inc. has been bullish today.

Why is Amgen Inc. going up?

AMGN stock is up 7.7% on Nov 5, 2025 18:06

• Amgen's strong bullish movement today can be attributed to its impressive Q3 earnings and sales beat, surpassing estimates and showcasing double-digit growth driven by key drugs.
• The company's decision to raise its 2025 outlook has instilled confidence in investors, leading to a positive market response.
• Investors are likely encouraged by the company's ability to consistently outperform expectations, as seen in the significant earnings and revenue surprises for the quarter.
• The market's positive reaction also reflects investors' anticipation of Amgen's future performance, as they delve deeper into the company's potential beyond just headline estimates.

AMGN Price Chart

AMGN Technical Analysis

AMGN News

Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.

https://www.zacks.com/stock/news/2785919/amgens-q3-earnings-sales-beat-2025-outlook-raised-stock-up

Amgen ( AMGN ) Q3 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +12.80% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2784948/amgen-amgn-q3-earnings-and-revenues-beat-estimates

A Look Into Amgen Inc's Price Over Earnings - Amgen ( NASDAQ:AMGN )

In the current session, Amgen Inc. ( NASDAQ:AMGN ) is trading at $291.80, after a 0.07% drop. Over the past month, the stock fell by 2.04%, and in the past year, by 7.92%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ...

https://www.benzinga.com/insights/news/25/10/48560044/a-look-into-amgen-incs-price-over-earnings

Amgen ( AMGN ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

https://www.zacks.com/stock/news/2781280/amgen-amgn-q3-earnings-preview-what-you-should-know-beyond-the-headline-estimates

Trending Today

ZCash ($ZEC) Crypto Forecast: Down 5.3% Today

Amgen Inc. Price History

05.10.2025 - AMGN Stock was up 5.3%

• Q3 earnings and revenues for Amgen (AMGN) surpassed expectations, indicating strong financial performance and potentially positive future outlook.
• Despite a slight decline in the current session, the stock has demonstrated resilience over the past month and year, suggesting a reliable long-term investment opportunity.
• Investors are closely monitoring Amgen's Q3 results, particularly focusing on the impact of newer drugs, biosimilar competition, and pricing pressures on the company's growth trajectory.
• The optimistic sentiment surrounding Amgen's financial performance and strategic positioning likely played a role in the bullish movement in the stock today.

05.10.2025 - AMGN Stock was up 7.7%

• Amgen's strong bullish movement today can be attributed to its impressive Q3 earnings and sales beat, surpassing estimates and showcasing double-digit growth driven by key drugs.
• The company's decision to raise its 2025 outlook has instilled confidence in investors, leading to a positive market response.
• Investors are likely encouraged by the company's ability to consistently outperform expectations, as seen in the significant earnings and revenue surprises for the quarter.
• The market's positive reaction also reflects investors' anticipation of Amgen's future performance, as they delve deeper into the company's potential beyond just headline estimates.

17.03.2025 - AMGN Stock was down 6.3%

• Amgen's stock experienced a bearish movement likely due to the lawsuit filed by Sandoz alleging illegal blocking of biosimilar competition for Enbrel, a significant revenue-generating arthritis drug.
• The legal battle and uncertainty surrounding the availability of Erelzi in the U.S. due to contested patents for Enbrel could have contributed to the negative market sentiment towards Amgen.
• Despite a slight gain in a recent trading session, the overall bearish trend today could be attributed to concerns over potential legal implications and competition affecting Amgen's market position and revenue streams.

05.01.2025 - AMGN Stock was up 6.6%

• During Q4, Amgen surpassed revenue and EPS expectations, impressing investors and boosting confidence in the company's growth trajectory.
• While facing a regulatory setback with the FDA's clinical hold on AMG 513 for obesity, Amgen's robust earnings performance outweighed concerns in the market.
• Favorable sentiment from influential investors and optimistic projections from analysts have contributed to Amgen's upward momentum.
• Despite regulatory hurdles, Amgen's financial strength and positive market outlook likely fueled today's significant bullish movement in the stock.

24.05.2025 - AMGN Stock was down 5.8%

• AMGN's stock price closed at $272.44, representing a significant -5.84% decrease compared to the previous day.
• The market response was influenced by the mixed outcomes of Part 1 of its Phase 2 study of MariTide, causing uncertainty among investors and resulting in downward pressure on the stock.
• Options trading activities indicate a prevailing bearish sentiment, with a majority of traders leaning towards pessimistic positions, exacerbating the selling pressure on AMGN's shares.
• Despite the current downward trend, some investors may view the decline in AMGN's stock price as an opportunity to potentially profit from the company's history of developing cutting-edge therapies in the long run.

09.03.2025 - AMGN Stock was down 5.7%

• The approval of Amgen's Uplizna for new rare autoimmune disease indications by the FDA was positive news for the company.
• Despite the positive developments with Uplizna, the stock saw a bearish trend, possibly due to profit-taking after recent spikes in the past year.
• The market's overall volatility and uncertainty may have contributed to the stock's decline despite the positive news.
• Investors might be cautious about the company's future performance, leading to a sell-off despite the overall market taking a dip.

02.06.2025 - AMGN Stock was up 5.2%

• Bemarituzumab, Amgen's gastric cancer drug, demonstrated enhanced survival rates in Phase 3 trials for advanced gastric cancer patients, likely bolstering investor trust in the company's pipeline and future revenue opportunities.
• The progress of MariTide, a monthly treatment for obesity in late-stage trials, signals Amgen's strategic move into the obesity market, attracting investor attention and optimism.
• The commencement of a Phase 3 study by VKTX on an obesity candidate might suggest growing competition in the obesity treatment sector, yet Amgen's established reputation and robust pipeline could help it maintain a competitive position.
• The prevailing positive market sentiment and Amgen's +1.03% stock price rise may indicate investor confidence in the company's innovative drug pipeline and its potential for future expansion and growth.

06.07.2025 - AMGN Stock was down 5.1%

• Despite surpassing earnings and revenue projections in the second quarter, the stock displayed downward movement.
• The market's reaction may be linked to concerns about the company's future growth potential despite the positive outcomes.
• Investors appear to be capitalizing on gains following a period of robust performance, causing a temporary decline in the stock value.
• Various broader market dynamics such as sector shifts or general market sentiment could be influencing Amgen's stock price negatively.

06.07.2025 - AMGN Stock was down 5.2%

• Despite surpassing Q2 earnings and revenue projections, Amgen (AMGN) faced a downturn in the market today.
• The market's reaction could be attributed to concerns regarding the company's future growth trajectory or provided guidance.
• Investors may have had higher expectations, prompting profit-taking and a temporary decline in the stock value.
• It is crucial to observe how Amgen addresses any potential underlying issues to determine the continuity of this bearish trend or whether it signals a buying opportunity for investors.

04.03.2025 - AMGN Stock was down 5.0%

• The FDA approval of Uplizna as the first drug for a chronic immune-mediated fibroinflammatory disorder should have been a positive catalyst for Amgen, but the bearish movement suggests otherwise.
• Despite positive clinical data and market resilience, the stock experienced a significant plunge, possibly due to profit-taking or broader market uncertainties.
• The bearish sentiment from deep-pocketed investors, as indicated by options trading, might have contributed to the downward pressure on Amgen's stock price.
• The mixed signals from the market, including a recent rise amidst a general market dip and a slight decrease in P/E ratio, could have added to the overall confusion and led to the bearish movement in AMGN today.

23.05.2025 - AMGN Stock was down 5.4%

• Today's bearish movement in AMGN may have been driven by market sentiment reflected through options trading, where a majority of traders displayed bearish tendencies.
• Noteworthy bearish actions by financial giants on Amgen might have caused apprehension among investors, prompting a sell-off of the stock.
• The analysis of options history revealing a higher percentage of bearish trades could have intensified the negative sentiment surrounding Amgen and contributed to today's significant bearish movement in the stock.

01.09.2025 - AMGN Stock was up 5.3%

• A noteworthy expansion of $650 million was unveiled by Amgen for its U.S. manufacturing network, reflecting a bolstered confidence in future growth prospects.
• The stock's bullish trend may be attributed to investors' optimism towards Amgen's strategic decision to enhance manufacturing capacity in response to evolving pharmaceutical tariff policies.
• Notwithstanding a minor market downturn, Amgen's proactive measures to reinforce manufacturing capabilities likely instilled confidence among investors, driving the stock's positive performance.